Showing 4891-4900 of 8730 results for "".
- SSS 2025: Focus on Disruptive Dermatology Innovationshttps://practicaldermatology.com/news/sss-2025-focus-on-disruptive-dermatology-innovations/2482981/The 2025 Science of Skin Summit will debut a new Innovations Forum feature this year dedicated to transformative products and emerging technologies shaping the future of dermatology. Scheduled for Saturday, September 6, 2025,
- Dual-Wavelength Laser Caps Gain Clinical Validation for Hair Density Gainshttps://practicaldermatology.com/news/dual-wavelength-laser-caps-gain-clinical-validation-for-hair-density-gains/2476121/KeraFactor announced that it will be spotlighting its dermatologist-developed hair health solutions this August in recognition of National Hair Loss Awareness Month, according to a news release from the manufacturer. The bran
- GLP-1 Users Drive Growth in Aesthetic Surgeryhttps://practicaldermatology.com/news/glp-1-users-drive-growth-in-aesthetic-surgery/2476140/Aesthetic surgery among patients with previous glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is increasing compared with postbariatric surgery patients, according to new research published in
- DermaRite Recalls Four Skin Care Products Over Burkholderia cepacia Contamination Riskhttps://practicaldermatology.com/news/dermarite-recalls-four-skin-care-products-over-burkholderia-cepacia-contamination-risk/2476092/DermaRite Industries has issued a nationwide recall of four over-the-counter antiseptic and analgesic products after tests detected contamination with Burkholderia cepacia complex (BCC), according to a statement released by
- Switching Biologics for Psoriasis May Improve Outcomes Without Added Risk: Studyhttps://practicaldermatology.com/news/switching-biologics-for-psoriasis-may-improve-outcomes-without-added-risk-study/2476064/Plaque psoriasis patients who are unresponsive to initial biologics may derive benefit from switching to another drug class, according to a new meta-analysis of 24 randomized controlled trials (RCTs). The review looked at da
- Study: Many May Avoid Cancer Treatment Due to Skin Side Effectshttps://practicaldermatology.com/news/study-one-third-may-avoid-cancer-treatment-due-to-skin-side-effects/2476010/A new pilot survey revealed that dermatologic side effects (DSEs) from anti-cancer therapies (ACTs) are widely misunderstood and could influence treatment decisions among patients in underserved communities. Researchers from th
- Deucravacitinib Plus Topical C/BD Effective in Moderate to Severe Psoriasis: Analysishttps://practicaldermatology.com/news/deucravacitinib-plus-topical-cbd-effective-in-moderate-to-severe-psoriasis-analysis/2476009/New research in the Journal of Drugs in Dermatology suggests that adding topical calcipotriene/betamethasone dipropionate (C/BD) foam to oral deucravacitinib therapy improves outcomes and quality of life in patients with moderate to severe chronic plaque p
- FDA Speeds Development of Hair Loss Drug Rezpegaldesleukinhttps://practicaldermatology.com/news/fda-speeds-development-of-nektars-autoimmune-hair-loss-drug/2475953/The FDA has granted Fast Track designation to the investigational biologic rezpegaldesleukin (Nektar Therapeutics) for the treatment of severe-to-very severe alopecia areata (AA) in adults and adolescents aged 12 and older who weigh at least 40 kg.
- Data Show HS Tied to Elevated Depression, Anxiety Riskhttps://practicaldermatology.com/news/data-show-hs-tied-to-elevated-depression-anxiety-risk/2475943/Patients with hidradenitis suppurativa (HS) face elevated risk of developing new-onset depression and anxiety compared with the general population, according to findings from a population-based cohort. The analysis included 1
- Report: IL-17 Therapies Target PsO and More, Poised for Growthhttps://practicaldermatology.com/news/report-il-17-therapies-target-pso-and-more-poised-for-growth/2475920/The interleukin-17 (IL-17) inhibitors market is expected to see sustained growth through 2034, driven primarily by next-gen agents and expanding indications in dermatology and rheumatology, according to a new report. Novel ag